Objective: To systematically evaluate and quantify the effects of rotigotine treatment on neuropsychiatric symptoms in Parkinson's disease (PD). Methods: We searched for articles involving randomized controlled trials (RCTs) that were published before September 1, 2017, in the PubMed, Clinical Trials, Cochrane Library, and EMBASE databases. A meta-analysis was performed to estimate changes in the scales used to assess neuropsychiatric symptoms. The data were analyzed using Cochrane Collaboration's Review Manager 5.3 software. Results: We identified 8 RCTs involving 1675 subjects. Compared with placebo treatment, treatment with the rotigotine transdermal patch significantly improved scores for the emotion/apathy domains of the Non-Motor Symptoms Scale (NMSS), Beck Depression Inventory-II (BDI-II), Apathy Scale (AS), the sleep/fatigue domains of the NMSS, the 8-item Parkinson's disease Questionnaire (PDQ-8) and the 39-item PDQ (PDQ-39) (emotion/apathy domain of the NMSS: MD = -2.5, 95% CI [-4.11, 0.89]; BDI-II: MD = -1.19, 95% CI [-2.30, 0.08]; AS: MD = -1.56, 95% CI [-2.67, 0.45]; sleep/fatigue domain of the NMSS: MD = 2.03, 95% CI [3.08, 0.98]; PDQ-8: MD = -4.93, 95% CI [-6.79, 3.07]; PDQ-39: MD = -3.52, 95% CI [-5.25, 1.79]; PDQ-8 and PDQ-39: SMD = -0.36,95% CI [0.49,0.23]). The results of the Parkinson's Disease Sleep Scale 2nd version (PDSS-2) were heterogeneous, and those on the Snaith-Hamilton Pleasure Scale (SHAPS) were not statistically significant (P = .61). Conclusion: The rotigotine transdermal patch effectively improved neuropsychiatric symptoms and quality of life in patients with PD. Further studies are warranted.